IDEXX Laboratories, Inc.
IDXX
$545.79
+3.21%
IDEXX Laboratories, Inc. is a global leader in the veterinary diagnostics and software industry, primarily developing, manufacturing, and distributing diagnostic products, equipment, and services for companion animal and livestock health. The company holds a dominant market position as a comprehensive, premium provider, operating an integrated ecosystem of in-clinic diagnostics, reference laboratory services, and practice management software that creates high switching costs and recurring revenue streams. The current investor narrative is focused on the company's ability to sustain its premium growth trajectory amidst a broader market rotation away from high-multiple stocks, with recent attention driven by its strong Q1 2026 results and raised long-term guidance, which signals resilient demand for pet healthcare services and diagnostic frequency.…
IDXX
IDEXX Laboratories, Inc.
$545.79
Related headlines
IDXX 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on IDEXX Laboratories, Inc.'s 12-month outlook, with a consensus price target around $709.53 and implied upside of +30.0% versus the current price.
Average Target
$709.53
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$437 - $710
Analyst target range
Analyst coverage for IDEXX is robust, with at least 10 distinct firms providing ratings, as evidenced by the institutional ratings data, indicating strong institutional interest. The consensus sentiment leans bullish, with recent actions including reiterated 'Buy' or 'Overweight' ratings from Stifel, Barclays, BTIG, JP Morgan, and Morgan Stanley, though firms like Piper Sandler and UBS maintain a 'Neutral' stance. The average analyst revenue estimate for the upcoming period is $6.98 billion, with an EPS estimate of $26.10, providing a basis for forward valuation calculations. The target price range is not explicitly provided in the data, but the implied upside or downside can be inferred from the consensus; given the current price of $528.79 and the prevailing bullish ratings, the average target likely implies moderate upside, though the wide dispersion in historical valuation multiples suggests analyst targets could vary significantly based on growth assumptions. The recent news of the company raising its long-term guidance is a positive catalyst that could lead to target price increases, supporting the bullish case, while the wide historical PE band indicates high uncertainty and sensitivity to growth projections, which is typical for a high-multiple growth stock undergoing a valuation correction.
Bulls vs Bears: IDXX Investment Factors
The bull case for IDXX is anchored in its unparalleled competitive moat, exceptional profitability, and resilient double-digit growth within the defensive pet healthcare sector. The bear case is dominated by its extreme valuation, which leaves the stock acutely vulnerable to multiple compression amid rising rates and growth deceleration. Currently, the bearish evidence from the pronounced price action and valuation risk carries stronger weight in the near term, as the market is actively repricing growth expectations. The single most important tension in the investment debate is whether IDXX's sequential growth deceleration and margin pressure are temporary or the beginning of a trend that would break the core justification for its premium multiple.
Bullish
- Dominant Market Position & High Switching Costs: IDEXX operates an integrated ecosystem of in-clinic diagnostics, reference lab services, and practice management software, creating significant switching costs and recurring revenue streams. This structural advantage underpins its premium valuation and supports sustained growth, as evidenced by its ability to raise long-term guidance.
- Robust Profitability & Exceptional ROE: The company maintains industry-leading profitability with a trailing net margin of 24.62% and a gross margin of 60.35% in Q4 2025. Its return on equity of 65.99% is exceptionally high, demonstrating efficient capital allocation and a powerful business model.
- Strong Revenue Growth & Raised Guidance: Q4 2025 revenue grew 14.28% year-over-year to $1.09 billion, and the company recently raised its long-term guidance based on resilient demand for pet healthcare. This signals confidence in sustained double-digit growth, a key justification for its premium valuation.
- Healthy Balance Sheet & Strong Cash Flow: IDEXX has a manageable debt-to-equity ratio of 0.67 and generates substantial cash, with TTM free cash flow of $1.05 billion. This financial strength provides flexibility for share repurchases and internal funding of growth initiatives without reliance on external capital.
Bearish
- Extreme Valuation Premium & Compression Risk: With a trailing PE of 51.15x and a forward PE of 32.02x, IDXX trades at a substantial premium to the broader healthcare sector. This high multiple makes the stock vulnerable to further compression, especially in a higher interest rate environment, as seen in its 31% decline from its 52-week high.
- Pronounced Technical Downtrend & High Volatility: The stock is down 23.36% over six months and 15.98% over three months, significantly underperforming the S&P 500. Its high beta of 1.574 indicates it is 57% more volatile than the market, amplifying downside during risk-off periods and requiring careful risk management.
- Sequential Growth Deceleration & Margin Pressure: Q4 2025 revenue growth of 14.28% YoY marks a slowdown from 17.8% in Q3 and 15.4% in Q2. Concurrently, gross margin has contracted sequentially from 62.62% in Q2 to 60.35% in Q4, suggesting potential cost pressures or unfavorable product mix shifts.
- Heavy Reliance on Sustained High Growth: The investment thesis is entirely dependent on the company maintaining its premium growth trajectory to justify its valuation. Any material slowdown below double-digits, as hinted by recent sequential deceleration, could trigger a severe multiple contraction given the PEG ratio of 2.3.
IDXX Technical Analysis
The stock is in a pronounced downtrend, having declined 15.98% over the past three months and 23.36% over the last six months, significantly underperforming the S&P 500 which gained 8.42% and 10.01% over the same periods, respectively. Currently trading at $528.79, the price sits approximately 31% above its 52-week low of $496.61 but is notably 31% below its 52-week high of $769.98, indicating it is in the lower half of its annual range and facing substantial selling pressure. The near-term momentum remains negative, with the stock down 8.95% over the past month, accelerating the longer-term decline and confirming a bearish trend divergence as the 1-year gain of 3.28% is being rapidly eroded. The high beta of 1.574 indicates the stock is approximately 57% more volatile than the broader market, which has amplified its downside during this risk-off period, and the significant relative weakness metrics, such as a -24.40% 3-month performance versus the SPY, underscore this pronounced underperformance. Key technical support is at the 52-week low of $496.61, while resistance is at the 52-week high of $769.98; a sustained break below support could signal a continuation of the downtrend towards lower levels, while a recovery above the $600-$650 zone would be needed to suggest a trend reversal. The stock's high volatility, evidenced by its beta and a maximum drawdown of -31.04%, necessitates careful risk management for investors considering a position during this corrective phase.
Beta
1.57
1.57x market volatility
Max Drawdown
-31.0%
Largest decline past year
52-Week Range
$497-$770
Price range past year
Annual Return
+5.3%
Cumulative gain past year
| Period | IDXX Return | S&P 500 |
|---|---|---|
| 1m | -7.4% | +4.0% |
| 3m | -12.8% | +8.2% |
| 6m | -21.7% | +11.5% |
| 1y | +5.3% | +24.3% |
| ytd | -18.5% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IDXX Fundamental Analysis
IDEXX's revenue trajectory remains positive but shows signs of sequential deceleration; the most recent Q4 2025 revenue was $1.09 billion, representing a solid 14.28% year-over-year growth, yet this marks a slowdown from the 17.8% YoY growth in Q3 2025 and the 15.4% growth in Q2 2025. The revenue segmentation reveals a product-heavy mix, with $652.44 million from Products and $438.14 million from Services for the latest quarter, indicating its core diagnostic hardware and consumables remain the primary growth driver. The company maintains robust profitability with a net income of $248.19 million in Q4 2025 and an industry-leading gross margin of 60.35%, though this gross margin has contracted slightly from 61.83% in Q3 2025 and 62.62% in Q2 2025, suggesting potential cost pressures or mix shifts. Operating margin for the quarter was 28.94%, and the trailing twelve-month net margin is a healthy 24.62%, demonstrating the company's ability to convert strong top-line growth into substantial bottom-line earnings. The balance sheet is solid with a manageable debt-to-equity ratio of 0.67 and a current ratio of 1.17, indicating sufficient short-term liquidity, while the company generates significant cash, evidenced by TTM free cash flow of $1.05 billion. A return on equity of 65.99% is exceptionally high, reflecting efficient use of shareholder capital, though this is partly leveraged by the debt on the balance sheet; the strong cash generation provides ample flexibility for continued share repurchases, as seen in recent quarters, and internal funding of growth initiatives.
Quarterly Revenue
$1.1B
2025-12
Revenue YoY Growth
+0.14%
YoY Comparison
Gross Margin
+0.60%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IDXX Overvalued?
Given the positive net income of $248.19 million in the latest quarter, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 51.15x and a forward PE of 32.02x, with the significant gap indicating the market expects strong future earnings growth to justify the current price. Compared to the broader healthcare sector, a trailing PE of 51x represents a substantial premium, which must be justified by IDEXX's superior growth profile, high profitability, and entrenched market leadership in veterinary diagnostics. Historically, the stock's own valuation has compressed from extreme levels; the current trailing PE of 51.15x is below its recent historical peaks seen in 2021 (e.g., 85.79x at the end of 2021) but remains elevated compared to its 2024 lows around 35-40x, suggesting the valuation is moderating but still pricing in high expectations. Trading near 12.59x Price-to-Sales and 33.75x Price-to-Book, the stock continues to command premium multiples across all metrics, reflecting its quality and growth characteristics, but the recent price decline indicates a market reassessment of these premium valuations in a higher interest rate environment.
PE
51.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 35x~86x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
37.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: IDEXX's primary financial risk is its absolute dependence on sustaining high growth to support its premium valuation. A trailing PE of 51.15x implies expectations for robust future earnings, making the stock highly sensitive to any growth slowdown, as seen in the sequential deceleration from 17.8% to 14.28% YoY revenue growth. While profitability is strong, the sequential contraction in gross margin from 62.62% to 60.35% over recent quarters indicates emerging cost or mix pressures that could threaten its industry-leading margins. The company's high return on equity of 65.99% is leveraged by its debt-to-equity of 0.67, introducing financial risk if earnings volatility increases.
Market & Competitive Risks: The paramount market risk is valuation compression. Trading at a significant premium to sector peers, IDXX is a prime candidate for de-rating if growth stock multiples continue to contract in a higher-for-longer rate environment. Its high beta of 1.574 means it is 57% more volatile than the market, amplifying downside during broad sell-offs. While its competitive position is strong, the premium valuation leaves no room for execution missteps or competitive disruption. The stock has already shown extreme relative weakness, underperforming the SPY by 24.40% over three months, confirming it is in the crosshairs of the current sector rotation.
Worst-Case Scenario: The worst-case scenario involves a combination of a growth slowdown accelerating beyond current trends and a sustained market-wide compression of growth stock multiples. This could trigger a cascade of analyst downgrades and a re-rating towards its historical lower-end PE range near 35x. A realistic downside could see the stock retest its 52-week low of $496.61, representing a -6% decline from the current price of $528.79. In a more severe bear case, if growth decelerates to single digits, the stock could fall further, potentially resulting in a total drawdown exceeding the recent maximum of -31.04% from its high.
